Clinical trial
PRE-ISPY Phase I/II Oncology Platform Program
NCT05868226
Study timeline
Study start (actual)2023-02-15Date precision: day
Registry last updated2026-09-30
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
HER2-positive Breast Cancerunresolved
Metastatic Cancerunresolved
Metastatic Breast Cancerunresolved
Metastaticunresolved
HER2-positive Metastatic Breast Cancerunresolved
HER2 Mutation-Related Tumorsunresolved
HER-2 Protein Overexpressionunresolved
HER2-negative Breast Cancerunresolved
Triple Negative Breast Cancerunresolved
HR Positiveunresolved
Hormone Receptor-positive Breast Cancerunresolved
Estrogen Receptor Positive Tumorunresolved
Solid Tumorunresolved
Solid Tumor, Adultunresolved
Solid Carcinomaunresolved
HER2 Low Breast Cancerunresolved
HER2 Low Breast Carcinomaunresolved
ER Positive Breast Cancerunresolved
PR-positive Breast Cancerunresolved
Minimal Residual Diseaseunresolved
Colo-rectal Cancerunresolved
Colon Cancerunresolved
Rectal Cancerunresolved
ctDNA Monitoringunresolved
Colorectal Neoplasmsunresolved
Colonic Neoplasmsunresolved
Rectal Neoplasmsunresolved
Neoplasm, Residualunresolved
Adenocarcinoma of Colonunresolved
Adenocarcinomaunresolved
Interventions
ALX148DRUG
Fam-Trastuzumab Deruxtecan-NxkiDRUG · verified · RxNorm: fam-trastuzumab deruxtecan-nxki
ZanidatamabDRUG · verified · RxNorm: zanidatamab
TucatinibDRUG · verified · RxNorm: tucatinib
TTX-MC138DRUG
Sponsors & collaborators
QuantumLeap Healthcare Collaborativelead sponsor
ALX Oncology Inc.collaborator
Pfizercollaborator
Jazz Pharmaceuticalscollaborator
TransCode Therapeuticscollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05868226 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.